Brief: Serina Therapeutics Says US FDA Places Clinical Hold On SER-252 Program
03/11/2025 11:44
Nov 3 (Reuters) - Serina Therapeutics Inc SER.A: SERINA THERAPEUTICS PROVIDES REGULATORY UPDATE ON SER-252 PROGRAM SERINA THERAPEUTICS INC - FDA PLACES CLINICAL HOLD ON SERINA'S SER-252 IND APPLICATION SERINA THERAPEUTICS INC - FDA REQUESTS ADDITIONAL INFORMATION ON EXCIPIENT IN FORMULATION SERINA THERAPEUTICS INC - EXPECTS FDA'S FORMAL CLINICAL-HOLD LETTER WITHIN 30 DAYS Source text: ID:nGNX7LN5Bs Further company coverage: SER.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Serina Therapeutics
See all newsBrief: Serina Therapeutics Inc Reports Cohort 1 Observations From Ser-252 Registrational Study In Advanced Parkinson’S Disease And Advances To Cohort 2
Brief: Serina Therapeutics - Offers Up To 12,500,000 Shares Of Common Stock By Roth Principal Investments - SEC Filing
Serina Therapeutics Q2 net loss widens on higher expenses
Brief: Serina Therapeutics Appoints Farrell Simon To Its Board Of Directors
Brief: Serina Therapeutics Completes Sentinel Dosing In Cohort 1 Of Phase 1B Registrational Trial Of SER-252